Form 4: Equillium Director Martha Demski Reports Option Repricing and Transactions
SEC Form 4 Filing
Director Martha Demski reports transactions related to stock options of Equillium, Inc. following the lapse of a holding period after repricing.
Summary
- Martha Demski, a director of Equillium, Inc., filed a Form 4 detailing changes in beneficial ownership.
- The report indicates transactions related to stock options, including the acquisition and disposal of derivative securities.
- The transactions occurred on February 14, 2025.
- The options were repriced on August 7, 2023, with the repricing taking effect after a holding period that ended on February 14, 2025.
- The repricing resulted in a lower exercise price of $0.785 per share for certain options.
- Demski now beneficially owns various director stock options with different exercise prices and expiration dates.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock option transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
Stock option repricing is a mechanism companies use to re-incentivize employees or directors when the stock price has fallen significantly below the original option exercise price. This can help retain talent and align their interests with shareholders.
Comparison to Industry Standards
- Stock option repricing is a relatively common practice in the biotechnology industry, especially for companies with volatile stock prices.
- Many companies use similar vesting schedules for stock options, typically vesting over a period of 1 to 4 years.
- The specific terms of the options, such as the exercise price and expiration date, are generally determined based on market conditions and company-specific factors.
Stakeholder Impact
- The repricing of stock options could potentially impact shareholder value, depending on the future performance of the company's stock.
- The repricing aims to incentivize the director, aligning her interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 08/07/2023 | Board of Directors approved the repricing of certain options. |
| 08/14/2023 | Closing price of the Company's common stock used for repricing. |
| 02/14/2025 | Date of transactions and lapse of holding period for repriced options. |
| 02/19/2025 | Date of Form 4 filing. |
| 06/10/2029 | Expiration date for some director stock options. |
| 05/18/2030 | Expiration date for some director stock options. |
| 05/25/2031 | Expiration date for some director stock options. |
| 05/23/2032 | Expiration date for some director stock options. |
Keywords
Form 4, Beneficial Ownership, Stock Options, Equillium, Director, Repricing, EQ
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.